Brokerages Expect Alder Biopharmaceuticals Inc (ALDR) to Announce -$1.08 EPS

Analysts forecast that Alder Biopharmaceuticals Inc (NASDAQ:ALDR) will announce earnings per share of ($1.08) for the current quarter, Zacks Investment Research reports. Zero analysts have issued estimates for Alder Biopharmaceuticals’ earnings. The highest EPS estimate is ($0.87) and the lowest is ($1.54). Alder Biopharmaceuticals posted earnings of ($0.97) per share during the same quarter last year, which would suggest a negative year-over-year growth rate of 11.3%. The firm is expected to report its next quarterly earnings report on Thursday, February 22nd.

On average, analysts expect that Alder Biopharmaceuticals will report full year earnings of ($5.14) per share for the current fiscal year, with EPS estimates ranging from ($5.94) to ($4.50). For the next fiscal year, analysts anticipate that the company will post earnings of ($3.90) per share, with EPS estimates ranging from ($5.42) to ($2.84). Zacks Investment Research’s earnings per share calculations are a mean average based on a survey of sell-side analysts that cover Alder Biopharmaceuticals.

Alder Biopharmaceuticals (NASDAQ:ALDR) last released its quarterly earnings data on Tuesday, November 7th. The biopharmaceutical company reported ($0.92) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.21) by $0.29. During the same quarter in the prior year, the business earned ($0.70) EPS.

A number of research firms have weighed in on ALDR. ValuEngine lowered shares of Alder Biopharmaceuticals from a “sell” rating to a “strong sell” rating in a research note on Friday, February 2nd. Mizuho restated a “buy” rating and set a $29.00 price objective on shares of Alder Biopharmaceuticals in a research note on Wednesday, January 31st. Canaccord Genuity set a $22.00 price objective on shares of Alder Biopharmaceuticals and gave the company a “buy” rating in a research note on Friday, January 12th. Zacks Investment Research lowered shares of Alder Biopharmaceuticals from a “hold” rating to a “sell” rating in a research note on Thursday, January 11th. Finally, BMO Capital Markets lifted their price target on shares of Alder Biopharmaceuticals to $26.00 and gave the stock an “outperform” rating in a research note on Tuesday, January 9th. Three equities research analysts have rated the stock with a sell rating, two have given a hold rating and eleven have assigned a buy rating to the company. The stock has an average rating of “Buy” and an average target price of $27.93.

Shares of Alder Biopharmaceuticals (NASDAQ:ALDR) opened at $13.80 on Wednesday. The firm has a market cap of $934.45, a PE ratio of -2.57 and a beta of 2.60. Alder Biopharmaceuticals has a 12 month low of $8.60 and a 12 month high of $25.45.

In related news, insider Mark James Litton sold 16,519 shares of the business’s stock in a transaction that occurred on Monday, November 13th. The shares were sold at an average price of $10.80, for a total transaction of $178,405.20. Following the completion of the sale, the insider now directly owns 116,451 shares in the company, valued at $1,257,670.80. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Insiders own 10.60% of the company’s stock.

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Vanguard Group Inc. grew its position in Alder Biopharmaceuticals by 5.5% during the second quarter. Vanguard Group Inc. now owns 3,626,573 shares of the biopharmaceutical company’s stock valued at $41,525,000 after buying an additional 187,871 shares during the period. Janus Henderson Group PLC bought a new stake in Alder Biopharmaceuticals during the second quarter valued at approximately $36,956,000. State Street Corp grew its position in Alder Biopharmaceuticals by 9.4% during the second quarter. State Street Corp now owns 1,944,755 shares of the biopharmaceutical company’s stock valued at $22,267,000 after buying an additional 167,642 shares during the period. Emerald Advisers Inc. PA grew its position in Alder Biopharmaceuticals by 9.6% during the fourth quarter. Emerald Advisers Inc. PA now owns 1,730,028 shares of the biopharmaceutical company’s stock valued at $19,809,000 after buying an additional 151,551 shares during the period. Finally, Pictet Asset Management Ltd. grew its position in Alder Biopharmaceuticals by 159.4% during the third quarter. Pictet Asset Management Ltd. now owns 1,650,540 shares of the biopharmaceutical company’s stock valued at $20,219,000 after buying an additional 1,014,290 shares during the period. Institutional investors own 96.78% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: This article was first reported by American Banking News and is the sole property of of American Banking News. If you are reading this article on another domain, it was illegally stolen and reposted in violation of U.S. & international trademark and copyright legislation. The original version of this article can be accessed at https://www.americanbankingnews.com/2018/02/07/brokerages-expect-alder-biopharmaceuticals-inc-aldr-to-announce-1-08-eps.html.

Alder Biopharmaceuticals Company Profile

Alder BioPharmaceuticals, Inc, is a clinical-stage biopharmaceutical company that discovers, develops and seeks to commercialize genetically engineered therapeutic antibodies with the potential to meaningfully transform current treatment paradigms. Alder’s lead pivotal-stage product candidate, eptinezumab, is being evaluated for migraine prevention.

Get a free copy of the Zacks research report on Alder Biopharmaceuticals (ALDR)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Alder Biopharmaceuticals (NASDAQ:ALDR)

Receive News & Ratings for Alder Biopharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alder Biopharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply